Literature DB >> 15276685

Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review.

Reiji Yoshimura1, Jun Nakamura, Koji Shinkai, Nobuhisa Ueda.   

Abstract

Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) may provide valuable information regarding central noradrenergic activity. In this article, we mainly reviewed about the associations between plasma MHPG levels and responses to antidepressant treatment. There exists heterogeneity of depression with regards to plasma levels of MHPG; in other words, depressed patients might be dichotomized into one group characterized by anxiety and/or perceptions of powerlessness with high plasma MHPG levels and another group characterized by psychomotor retardation with low plasma MHPG levels. In addition, it is possible that patients with lower pretreatment MHPG levels might respond to drugs that affect both noradrenergic neurons and serotonergic neurons or predominantly noradrenergic neurons. On the other hand, patients with higher pretreatment MHPG levels might respond to drugs that affect predominantly serotonergic neurons or GABAergic neurons. It is possible to predict the responses to antidepressant drugs by means of plasma MHPG levels in depressed patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276685     DOI: 10.1016/j.pnpbp.2004.01.008

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  8 in total

Review 1.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

2.  COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study.

Authors:  Kenji Hayashi; Reiji Yoshimura; Shingo Kakeda; Taro Kishi; Osamu Abe; Wakako Umene-Nakano; Asuka Katsuki; Hikaru Hori; Atsuko Ikenouchi-Sugita; Keita Watanabe; Satoru Ide; Issei Ueda; Junji Moriya; Nakao Iwata; Yukunori Korogi; Marek Kubicki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-25       Impact factor: 2.570

3.  Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder.

Authors:  Kiyokazu Atake; Reiji Yoshimura; Hikaru Hori; Asuka Katsuki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-03       Impact factor: 2.570

Review 4.  Biomarkers for depression: recent insights, current challenges and future prospects.

Authors:  Rebecca Strawbridge; Allan H Young; Anthony J Cleare
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-10       Impact factor: 2.570

5.  Changes in fatigue, autonomic functions, and blood biomarkers due to sitting isometric yoga in patients with chronic fatigue syndrome.

Authors:  Takakazu Oka; Tokusei Tanahashi; Nobuyuki Sudo; Battuvshin Lkhagvasuren; Yu Yamada
Journal:  Biopsychosoc Med       Date:  2018-04-10

6.  Bilateral Transcranial Magnetic Stimulation on DLPFC Changes Resting State Networks and Cognitive Function in Patients With Bipolar Depression.

Authors:  Reza Kazemi; Reza Rostami; Sanaz Khomami; Golnaz Baghdadi; Mehdi Rezaei; Masahiro Hata; Yasunori Aoki; Ryouhei Ishii; Masao Iwase; Paul B Fitzgerald
Journal:  Front Hum Neurosci       Date:  2018-09-05       Impact factor: 3.169

7.  The longitudinal effects of seated isometric yoga on blood biomarkers, autonomic functions, and psychological parameters of patients with chronic fatigue syndrome: a pilot study.

Authors:  Takakazu Oka; Tokusei Tanahashi; Battuvshin Lkhagvasuren; Yu Yamada
Journal:  Biopsychosoc Med       Date:  2019-11-05

8.  Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study.

Authors:  Reiji Yoshimura; Taro Kishi; Kiyokazu Atake; Asuka Katsuki; Nakao Iwata
Journal:  Front Psychiatry       Date:  2018-02-28       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.